ClinicalTrials.gg
CompletedNCT03754660ATMOSUpdated May 7, 2025

This Study Tests the Safety of Inhaled BAY1237592, How the Drug is Tolerated and How it Effects Patients With High Blood Pressure in the Arteries of the Lungs in the Two Different Disease Groups Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

A Phase 1 interventional study of BAY1237592 in Hypertension, Pulmonary, sponsored by Bayer. Completed at 8 sites in 4 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-05-07.

Primary conditionPulmonary Arterial HypertensionRegistry: Hypertension, PulmonaryReclassifiedWhy we changed it
Registry
Hypertension, Pulmonary — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pulmonary Arterial Hypertension
Why
  1. The study's title name Pulmonary Arterial Hypertension, a narrower term within Hypertension, Pulmonary.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Bayer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
38
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies in Pulmonary Arterial Hypertension by Bayer — none open to participants now, 1 under way, 1 of them phase 3. Pulmonary Arterial Hypertension · Bayer.

Started
2019
with 1 other
Phase 1
Only one
of the 19
Registered
17th of 19
by date

Among the 19 studies in Pulmonary Arterial Hypertension by Bayer, this one is one of 2 that started in 2019, is the only one in phase 1, and was the 17th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

None of the 19 studies in Pulmonary Arterial Hypertension by Bayer is open now. The open studies under Pulmonary Arterial Hypertension, anywhere →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Pulmonary Arterial Hypertension by Bayer as a file.
02

Study summary

In this trial the effects of the inhaled drug BAY1237592 will be studied in patients with high blood pressure in the pulmonary blood vessels due to Pulmonary Arterial Hypertension (PAH) and due to Chronic Thromboembolic Pulmonary Hypertension (CTEPH). Pulmonary hypertension is characterized by the elevation of pressure in the pulmonary arteries (PAP) and of the pulmonary vascular resistance (PVR) leading to increased workload of the right chamber of the heart to eject blood against this elevated resistance. The goal of this study is to measure the safety and tolerability of the drug as well as the reduction of the PVR at different doses

In Part A patients without specific treatment for PH (untreated patients) will be tested. In Part B also patients stably pre-treated with specific PH drugs will be studied in combination with the new inhaled drug

03

Conditions studied

  • Hypertension, Pulmonary

Browse trials for

Keywords

  • PAH
  • CTEPH
  • pulmonary arterial hypertension
  • chronic thromboembolic pulmonary hypertension
04

In context

Pulmonary Arterial Hypertension Reclassified

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.

This study's enrollment of 38 is close to the median of 40 across 477 interventional studies indexed under Pulmonary Arterial Hypertension.

Browse Pulmonary Arterial Hypertension studies →

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Compared within Pulmonary Arterial Hypertension, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension, Pulmonary. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Patients with PAH or CTEPH undergoing medically indicated routine invasive diagnostics
  • Men and women aged 18 to 80 years

Part A:

  • Untreated patients: Therapy-naïve patients (defined as off treatment with PDE-5 inhibitors, endothelin receptor antagonists, prostanoids, or other sGC stimulators/activators) with PAH or CTEPH or patients pre-treated with these medications who have to undergo a drug specific at the discretion of the investigator for least 24 h prior to Day -1 if medically safe

Part B:

  • Untreated patients with PAH or CTEPH:

    -- Group 1 (total will be summed up with corresponding dosage group from Part A)

  • Pre-treated patients with PAH or CTEPH:

    • Group 2: Pre-treated patients with any kind of monotherapy* for PAH/CTEPH
    • Group 3: Pre-treated patients with any kind of double combination therapy* for PAH/CTEPH * patients receiving inhaled Iloprost, and patients who are known responders to iNO are excluded

Main Exclusion Criteria:

  • Medical history indicating a different cause for PH than PAH or CTEPH according to the guidelines of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), such as significant left heart disease, valvular disease, or structural heart defects, as assessed by the investigator, significant pulmonary disease or clinical suspicion of pulmonary venoocclusive disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

06

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Untreated patients (Part A and Part B)

    Part A: Untreated PAH and CTEPH patients will be enrolled to test 5 ascending doses of BAY1237592 with 4 patients per dose group up to a maximum dose of 4000 µg. Part B: The highest safe, well tolerated and effective dose of Part A will be tested in further untreated patients.

    Drug: BAY1237592

  • Experimental
    Monotherapy (Part B)

    The highest safe, well tolerated and effective dose chosen from Part A will be tested in pre-treated patients with any kind of monotherapy for PAH/CTEPH.

    Drug: BAY1237592

  • Experimental
    Combined therapy (Part B)

    The highest safe, well tolerated and effective dose from Part A will be tested in pre-treated patients with any kind of double combination treatment for PAH/CTEPH.

    Drug: BAY1237592

Interventions

  • Oral inhalation with dry powder inhaler, single dose.

07

What researchers measure

Primary outcomes

  1. Peak percent reduction in PVR (Pulmonary vascular resistance) from "baseline 2" for untreated patients

    PVR = 80\* (PAP - PCWP) / CO (dyn·sec·cm-5) * PAP = pulmonary arterial pressure * PCWP = pulmonary capillary wedge pressure * CO = cardiac output

    Time frame: Up to 5 hours post inhalation of BAY1237592 compared to "baseline 2"

  2. Peak percent reduction in PVR from "baseline" for pre-treated patients

    PVR = 80\* (PAP - PCWP) / CO (dyn·sec·cm-5)

    Time frame: Up to 5 hours post inhalation of BAY1237592 compared to "baseline"

Secondary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs)

    Time frame: Up to 7 days after treatment

08

Study locations

8 sites
  • Medizinische Universität Graz
    Graz, 8036, Austria
  • Vseobecna fakultni nemocnice v Praze
    Praha 2, 12808, Czechia
  • Institut Klinicke a Experimentalni Mediciny
    Praha 4, 140 21, Czechia
  • Krankenhaus Neuwittelsbach
    München, Bayern 80639, Germany
  • Universitätsklinikum Regensburg
    Regensburg, Bayern 93042, Germany
  • Universitätsklinikum Giessen und Marburg
    Gießen, Hessen 35392, Germany
  • Universitätsklinikum Carl Gustav Carus Dresden
    Dresden, Sachsen 01307, Germany
  • Szpital Specjalistyczny im. Jana Pawla II
    Krakow, 31-202, Poland
09

References and documents

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2019 to primary completion in Apr 2022, 39 months.

Of 34 industry-sponsored phase 1 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 17. This study's 39 months is above that.

Counting every sponsor, half of 45 studies reached it within 9 months; a quarter within 2 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2018
First posted
Nov 27, 2018
StartActual
Jan 21, 2019
Primary completionActual
Apr 24, 2022
CompletionActual
Nov 3, 2022
Last update
May 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03754660
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Nov 27, 2018
Start date
Jan 21, 2019
Primary completion
Apr 24, 2022
Completion
Nov 3, 2022
Last update
May 7, 2025

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mosliciguat

Start the discussion